A dedicated cancer hospital affiliated with Peking University, internationally recognised for gastric cancer research, melanoma treatment in Asian patients, and immunotherapy trials that have informed how oncologists approach these cancers in China and the region. For patients with gastric cancer, colorectal cancer, or advanced melanoma, PKU Cancer Hospital may offer access to physicians who are active at the frontiers of the research — China Care helps you work out whether it's a suitable option for your specific case. China Care coordinates international patient access via the VIP Oncology Service.
Peking University Cancer Hospital (北京大学肿瘤医院) is one of China's premier specialist oncology institutions, founded in 1976 and affiliated with Peking University. Its international reputation is built primarily on two areas: gastric cancer — where it holds a leading research ranking — and melanoma, where it runs a leading programme in Asia for patients with the mutation profiles most commonly found in Asian populations.
The hospital's immunotherapy research has produced findings that have informed treatment guidelines in China and internationally. Its oncologists contribute to clinical protocols used domestically and referenced by international oncology bodies. For patients seeking cancer treatment in China at an institution at the research frontier, PKU Cancer Hospital represents the highest tier of academic oncology.
The hospital treats the full range of gastrointestinal and gynaecological malignancies alongside its specialist programmes. Colorectal cancer, gastroesophageal cancer, and gynaecological oncology all benefit from the proximity to the gastric cancer and immunotherapy programmes — shared protocols, integrated trial portfolios, and the cross-fertilisation of research insights between departments.
PKU Cancer Hospital holds a leading position in gastric cancer research. Its oncologists have authored the clinical guidelines that govern how gastric cancer is treated domestically and have contributed landmark publications that informed international practice. For patients with gastric cancer, gastroesophageal junction cancer, or related GI malignancies, no institution in China has deeper disease-specific expertise.
The immunotherapy programme at PKU Cancer Hospital has generated data that has informed both Chinese and international treatment guidelines. Its clinical trial portfolio covers novel checkpoint inhibitor combinations and biomarker-driven patient selection approaches. Patients whose tumours have not responded to standard immunotherapy regimens may qualify for trials investigating next-generation approaches not yet available elsewhere.
Melanoma in Asian patients commonly presents with acral lentiginous or mucosal subtypes with distinct mutation profiles — often KIT or BRAF non-V600 — compared to UV-driven melanoma in Western populations. PKU Cancer Hospital's melanoma programme has extensive experience with these Asian-specific subtypes and the targeted and immunotherapy regimens appropriate for them. Patients who have received suboptimal treatment based on protocols designed for Western melanoma cohorts often find more appropriate options here.
Finding a hospital's name is easy. Knowing whether it's actually the right one for your situation is much harder — that's where China Care helps.
Most international patients researching PKU Cancer Hospital are unsure whether it's genuinely the right fit for their case, or whether another hospital might serve them better. China Care helps you answer questions like:
PKU Cancer Hospital specialises in gastrointestinal oncology, immunotherapy, and melanoma, with strong complementary programmes in colorectal and gynaecological cancers. The following departments are most frequently accessed by international patients coordinated through China Care.
Finding a hospital is the easy part. Understanding whether it's the right one for your situation is harder — China Care guides you through that, from initial guidance through to on-the-ground support in Beijing.
Send your pathology reports including biopsy results, IHC panel, and molecular profiling where available — especially HER2, PD-L1, MMR/MSI, RAS/BRAF status for GI cancers; KIT, BRAF, and NRAS status for melanoma. Include staging investigations, imaging, and full prior treatment history. China Care prepares a structured bilingual case summary within 1–2 working days.
full pathology & molecular profiling · 1–2 daysIf it makes sense to go further, Case Investigation looks into whether this hospital is genuinely a suitable option for your case — before you commit to travelling. This includes a proxy consultation: China Care attends PKU Cancer Hospital in person and consults with the relevant oncology specialist on your behalf. The specialist reviews your case summary, gives initial clinical direction, and flags whether your case may qualify for any active clinical trials, with the outcome reported back to you with real-time voice interpretation.
This is a paid service, charged at a fixed fee covering hospital registration, the proxy consultation, and voice interpretation, agreed with you upfront. Already in China? Skip this step — China Care can arrange direct escort and interpretation for your own visit instead.
proxy consultation · fixed fee · results same dayWith the specialist's initial direction confirmed, you travel to Beijing for your own in-person consultation at the VIP Oncology Service. The specialist issues a formal treatment plan and cost estimate — this step cannot be completed remotely at a public hospital. Cases under consideration for clinical trial enrolment may receive an additional eligibility review. China Care's bilingual coordinator accompanies you throughout.
in-person consultation · treatment plan & cost estimate issuedAdmission is arranged through the VIP Oncology Service once you confirm treatment. China Care's coordinator remains available throughout your stay for language support and coordination with hospital administration.
All treatment fees are paid directly to the hospital in Chinese yuan (RMB). PKU Cancer Hospital does not accept international credit cards for inpatient treatment. A deposit is required at admission; the balance is settled before discharge. China Care does not collect or handle medical payments.
VIP Oncology Service · RMB payment direct to hospitalFull bilingual discharge documentation is provided at discharge. An English-language summary is prepared for your home oncologist. For patients enrolled in clinical trials, follow-up schedules and reporting protocols are confirmed at discharge. China Care provides post-discharge support for any queries.
bilingual documentation · post-discharge supportWhichever stage you're at, China Care's role is the same: help you make an informed decision, not just a booking.
Understand your options before travelling — including whether PKU Cancer Hospital or another hospital is a suitable fit for your case.
Learn more →Appointments, interpreters, and hospital coordination once you're ready to move forward.
Learn more →Support before, during, and after treatment in China — from admission through to follow-up care.
Learn more →We'll help you understand whether PKU Cancer Hospital — or another hospital in China — may be a better option for your situation.
China Care coordinates your referral to PKU Cancer Hospital's international patient team. Treatment costs are quoted directly by the hospital. We never add to, inflate, or mark up the hospital's quoted treatment cost.